Skip to search formSkip to main contentSkip to account menu

VPA 985

Known as: VPA-985 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lixivaptan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is a non… 
2007
2007
LA TERAPIA CON GLI ANTAGONISTI DELLA VASOPRESSINA: GLI ACQUARETICI
NTRODUZIONEGli acquaretici costituiscono una sottofamiglia diantagonisti non peptidici della vasopressina. Questoormone, prodotto… 
Review
2006
Review
2006
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
2005
2005
(4-Substituted-phenyl)-(5H-10,11-dihydro-pyrrolo [2,1-c][1,4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators.
2000
2000
The design, synthesis and physical chemical properties of novel human vasopressin V2-receptor antagonists optimized for parenteral delivery.
2000
2000
The effects of VPA-985, a vasopressin receptor antagonist, on water metabolism in patients with hyponatremia: A multi-center randomized placebo controlled trial
1999
1999
5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists.
1999
1999
Selective V 2-Receptor Vasopressin Antagonism Decreases Urinary Aquaporin-2 Excretion in Patients with Chronic Heart Failure
Aquaporin-2 (AQP-2), a water channel located on the apical membrane of collecting duct cells, regulates water reabsorption under… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)